SCHEMBL2765602

SCHEMBL2765602

Cc1cc(N2CC(NC(=O)Oc3ccc(Br)s3)CC2=O)ccc1C(=O)N1CCC[C@H]1CO

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.42
POLB P06746 3/20 0.42
TP53 P04637 3/20 0.37
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2766198 1.00 LMNA (0.42) LMNAPOLBTP53MAPT
SCHEMBL2768238 0.93 LMNA (0.42) LMNAPOLBTP53MAPT
SCHEMBL2767030 0.92 LMNA (0.41) LMNAPOLBTP53MAPT
SCHEMBL2767520 0.92 LMNA (0.41) LMNAPOLBTP53MAPT
SCHEMBL2766628 0.92 LMNA (0.41) LMNAPOLBTP53
SCHEMBL2766953 0.92 LMNA (0.41) LMNAPOLBTP53MAPT
SCHEMBL2765621 0.92 LMNA (0.41) LMNAPOLBTP53
SCHEMBL2765232 0.92 POLB (0.43) LMNAPOLBTP53MAPT
SCHEMBL2766127 0.91 LMNA (0.43) LMNAPOLBTP53MAPT
SCHEMBL2768167 0.90 LMNA (0.41) LMNAPOLBTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858890-B1 NOVEL ANTITHROMBOTIC SUBSTITUTED PYRROLIDINONES, THE PRODUCTION AND USE THEREOF IN THE FORM OF MEDICAMENTS BOEHRINGER INGELHEIM PHARMA (DE) 2010-04-14 EP disclosed
EP-1858890-A1 NOVEL ANTITHROMBOTIC SUBSTITUTED PYRROLIDINONES, THE PRODUCTION AND USE THEREOF IN THE FORM OF MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2007-11-28 EP disclosed
WO-2006089909-A1 NOVEL ANTITHROMBOTIC SUBSTITUTED PYRROLIDINONES, THE PRODUCTION AND USE THEREOF IN THE FORM OF MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-08-31 WO disclosed